Belzutifan induced strong responses in patients with von Hippel-Lindau disease-associated kidney cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong ...
Nov 24, 2021
0
21